Internal stimuli-responsive nanocarriers for controlled anti-cancer drug release: a review

Ther Deliv. 2023 Sep;14(9):595-613. doi: 10.4155/tde-2023-0041. Epub 2023 Oct 25.

Abstract

Cancer disease is one of the most frequent life-threatening, with a high fatality rate worldwide. However, recent immunotherapy studies in various tumours have yielded unsatisfactory outcomes, with just a few individuals experiencing long-term responses. To overcome these issues, nowadays internal stimuli-responsive nanocarriers have been widely exploited to transport a wide range of active substances, including peptides, genes and medicines. These nanosystems could be chemically adjusted to produce target-based drug release at the target location, minimizing pathological and physiological difficulties while increasing therapeutic efficiency. This review highlights the various types of internal stimuli-responsive nanocarriers and applications in cancer diagnosis. This study can provide inspiration and impetus for exploiting more promising internal stimuli-responsive nanosystems for drug delivery.

Keywords: cancer; nanocarrier; stimuli-responsive drug-delivery system; tumor imaging.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents* / therapeutic use
  • Drug Carriers / chemistry
  • Drug Delivery Systems
  • Drug Liberation
  • Humans
  • Nanoparticles* / chemistry
  • Neoplasms* / diagnosis
  • Neoplasms* / drug therapy

Substances

  • Drug Carriers
  • Antineoplastic Agents